Harm Reduction· Daily Pulse

Xylazine's Treatment Gap: Why 'Tranq' Wounds and Withdrawal Still Lack a Clinical Playbook

Naloxone reverses opioid overdose but does nothing for xylazine sedation. Two years after xylazine was declared an emerging threat, the field still lacks FDA-approved protocols.

ByThe Rize NewsroomMay 28, 20262 min readXylazine

Xylazine’s Treatment Gap: Why ‘Tranq’ Wounds and Withdrawal Still Lack a Clinical Playbook

Xylazine — the veterinary sedative now found in fentanyl supplies in at least 30 states — presents a clinical problem that has no clean solution. Unlike opioids, xylazine is not reversed by naloxone. Unlike benzodiazepines, there is no approved reversal agent. Unlike any other adulterant in the current drug supply, it causes a distinctive wound syndrome — necrotic skin ulcers that can progress to limb-threatening infections requiring amputation — even at injection sites far from where the drug entered the body.

Where the Science Stands

On overdose reversal: Naloxone remains essential for fentanyl-xylazine overdoses because fentanyl is usually the lethal component. But after the opioid component is reversed, patients may remain deeply sedated from xylazine — sometimes for hours. Current guidance is to administer naloxone, place the person in the recovery position, and monitor. There is no pharmacological shortcut.

On wound care: The Philadelphia Consensus (2025) established surgical best practices: debridement of necrotic tissue, evaluation for systemic infection, long-term wound dressings with individualized follow-up. In practice, this care is inaccessible to most people who use drugs — they lack housing, transportation, and often consistent access to clinicians willing to provide non-judgmental wound care.

On withdrawal: Xylazine withdrawal is not opioid withdrawal. It involves agitation, hypertension, and hypersensitivity — a syndrome that resembles alpha-2 agonist rebound. Clonidine has been used off-label to manage it, but no controlled trials exist.

The Research Deficit

A 2023 Harm Reduction Journal review explicitly named xylazine treatment as a field with critical research deficits. As of mid-2026, that assessment remains accurate. No FDA-approved treatments exist. No clinical trials are listed on ClinicalTrials.gov specifically for xylazine withdrawal management. Harm reduction programs distributing fentanyl/xylazine test strips — recently subject to federal rollback — are one of the few evidence-adjacent interventions available.

Why This Matters for People in Recovery

If you or someone you know has wounds that aren’t healing, or has experienced prolonged sedation after opioid overdose reversal with naloxone, xylazine may be involved. Rize’s treatment directory includes programs that provide wound care and low-barrier substance use support. Find help near you →

Crisis resources: SAMHSA Helpline 1-800-662-4357 | 988 Suicide & Crisis Lifeline (call or text 988)

Sources Cited

01.A
Reducing the harms of xylazine: clinical approaches and research deficitsHarm Reduction Journal
02.A
Philadelphia Consensus on Xylazine Wound ManagementSurgiColl

Filed Under

treatmentharm-reductionscienceXylazineHarm ReductionFentanyl

More from this section

Harm Reduction

69,973 Deaths. The Number That Proves Harm Reduction Works—and the Policy Quietly Undoing It.

CDC provisional data projects 69,973 overdose deaths for 2025—a 13.9% decline. The same spring, SAMHSA ended federal funding for fentanyl test strips. The drug supply has never been more dangerous.

Harm Reduction

Responding to the Emerging Threat of Xylazine

On April 24, SAMHSA banned federal funding for fentanyl, xylazine, and medetomidine test strips for public distribution — precisely as the June 2026 Labcorp report shows medetomidine in 91% of Philadelphia's fentanyl supply. The policy contradiction that kills people who use drugs.

Harm Reduction

The Drug Inside the Drug: How Medetomidine Is Breaking Every Overdose Response Playbook

Medetomidine, a veterinary sedative 200 times more potent than xylazine, has displaced xylazine in Philadelphia's fentanyl supply and is confirmed in nine states. It produces sedation that naloxone cannot reverse, withdrawal that requires ICU-level care in 91% of hospitalized patients, and clinical presentations that emergency departments are consistently misidentifying.